At Endo 2023, one of the most prominent endocrinology conferences, Bone Health Technologies presented pivotal trial data for its innovative product, Osteoboost. This novel treatment is designed to fight low bone mass in postmenopausal women. The technology, which received Breakthrough Device Status, has been filed for Class 2 Prescription De Novo Approval with the FDA.
The study showcased was double-blinded and sham-controlled, including 126 postmenopausal women. It focused on the change in vertebral strength. Subjects using Osteoboost experienced an 82% reduction in the rate of bone strength loss and an 85% reduction in loss of bone density, as compared to the sham group.
Laura Bilek, Ph.D., who led the study, and Laura Yecies, CEO of Bone Health Technologies, both hailed the study as a breakthrough. They emphasized how Osteoboost empowers women to maintain bone health without the adverse effects associated with pharmaceutical interventions.
Osteoboost’s breakthrough in non-pharmacological treatment of osteopenia represents a monumental step in the field of bone health.
